Aurobindo Pharma Limited — Investor Meet, 13-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Aurobindo Pharma reported strong Q1 FY27 financial results: consolidated revenues grew 16% to Rs. 9,150 crores, with PAT at Rs. 1,032 crores. Operating EBITDA hit Rs. 1,924 crores (21% margin). Key drivers included 17% growth in formulations and 38% in growth markets. The Lannett acquisition is complete, with Advair launching in August, expected to boost US presence. Biosimilar pipeline advances with imminent US filings and EU progress. TheraNym CMO revenue is visible from 2028. The company maintains its FY27 guidance of double-digit revenue growth and >21% EBITDA margin, reflecting a confident outlook on strategic initiatives.